Literature DB >> 22855845

Infliximab therapy in hematologic malignancies: handle with care.

Fabio Stagno, Paolo Vigneri, Alessandra Cupri, Silvia Rita Vitale, Francesco Di Raimondo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22855845      PMCID： PMC3409801          DOI： 10.3324/haematol.2012.067934

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

Authors:  S Lori Brown; Mark H Greene; Sharon K Gershon; Evelyne T Edwards; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-12

2.  Acute myelogenous leukaemia following etanercept therapy.

Authors:  G Bakland; H Nossent
Journal:  Rheumatology (Oxford)       Date:  2003-07       Impact factor: 7.580

3.  Myeloproliferative disorders in patients with inflammatory bowel disease on anti-TNF-α therapy: report of two cases and review of the literature.

Authors:  Monika Fischer; Debra J Helper; Michael V Chiorean
Journal:  Inflamm Bowel Dis       Date:  2011-02       Impact factor: 5.325

4.  Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab.

Authors:  F Broussais; M Kawashima; H Marotte; P Miossec
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

5.  Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells.

Authors:  T Murase; T Hotta; H Saito; R Ohno
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

6.  Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.

Authors:  Frédéric Baron; Stefan Suciu; Sergio Amadori; Petra Muus; Heinz Zwierzina; Claudio Denzlinger; Michel Delforge; Antoine Thyss; Dominik Selleslag; Karel Indrak; Gert Ossenkoppele; Theo de Witte
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

7.  Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.

Authors:  H Fidder; F Schnitzler; M Ferrante; M Noman; K Katsanos; S Segaert; L Henckaerts; G Van Assche; S Vermeire; P Rutgeerts
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.